Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Novartis Sale Of US Oral Generics Unit Seems Unlikely

The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may be considering a sale of the latter go against Novartis' previous comments and observers are struggling to see the rationale behind such a move.

Generic Drugs M & A Biosimilars

Arix And China's Fosun Ink A Strategic Partnership

A new strategic partnership has been forged between Arix Bioscience and China's Fosun International to develop new business opportunities in China.

Deals StartUps and SMEs Commercial

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
ImmunoOncology Cancer Approvals

Exploring Sanofi's Revamped IO Pipeline

In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.

Business Strategies ImmunoOncology Research and Development Strategies
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Set Alert for Commercial

Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition

Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.

Deals Business Strategies M & A

Strides' Net Profit Dives But Regulated Markets Seen Delivering Growth

Strides Shasun has reported third-quarter net profit plunged by 57% but the Indian firm says performance will improve in coming quarters thanks to its regulated market focus, and analysts agree earnings look set to rise.
Commercial Companies Sales & Earnings

Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?

Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.

Commercial Companies

Osteoarthritis Stem Cell Therapy Could Be On Sale In India By 2020

A novel Indian stem cell injection treatment intended to slow down joint damage caused by osteoarthritis and potentially avert replacement surgery will undergo domestic Phase III trials this year and could be on sale in the country by 2020 under a licensing deal between Alkem Laboratories and biotech firm Stempeutics.

Commercial Deals

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies

Roche To Build RWE Cancer Data Extraction Role With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Business Strategies Commercial

Pay, Patriots And The Art of Promise: What Results Season Taught Us

Most of the biggest pharmaceutical companies that pay taxes in Europe or North America have told the world how they got on in 2017. So what, other than the corrective value of financial performance minutiae, did we learn?

Business Strategies Biosimilars

Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal

Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.

Rare Diseases Deals

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

FDA Deputy On CRLs: 'It's Not Our Property To Release'

US FDA Principal Deputy Commissioner Rachel Sherman said during the BIO CEO & Investor conference that while investors and others would like to see complete response letters, the agency's hands are bound when it comes to their full release. Sherman also commented on FDA's focus for right-to-try legislation.

FDA Complete Response Letters Policy

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

J&J subsidiary Janssen's Erleada (apalutamide) is the first therapy approved for non-metastatic castration-resistant prostate cancer (nmCRPC). The US FDA decision came about two months early, but the drug – priced at $10,920 per month, or $131,040 annually – may soon face competition.
Approvals Cancer

Bayer In FDA's Bad Books Over Facility Failures

Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling  products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.

Manufacturing FDA

Vertex Eyes Triple Glory After Hat Trick of CF Approvals

Symdeko, which will have a wholesale price of $292,000 per year, has got the green light in the US, adding to Vertex' already-approved cystic fibrosis treatments Kalydeco and Orkambi. Now, focus will shift onto its role in potential triple combinations for the disease.

Rare Diseases Approvals

Research & Development Explore this Topic

Set Alert for Research & Development

Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate

In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.

Cardiovascular Research & Development Market Intelligence

Lilly Halts Hanmi BTK Inhibitor Trial For RA, Mulls Other Indications

Hanmi Pharmaceutical shares fell sharply on the news Lilly has halted Phase II trials of the South  Korean firm’s BTK inhibitor for rheumatoid arthritis. But Hanmi says its license contract remains intact and that the two firms are discussing the potential development of the molecule for other indications.

Research & Development South Korea

Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

The big-selling psoriasis drug has achieved healthy clinical remission rates in a Phase II trial for ulcerative colitis, and Celgene believes Otezla and another potential blockbuster, ozanimod, will help it build a significant presence in inflammatory bowel disease.

Gastrointestinal Clinical Trials
UsernamePublicRestriction

Register

Advertisement